Is AptarGroup, Inc. (ATR) a Buy, Sell, or Hold?
AptarGroup, Inc.
NYSE:ATR
$128.28 USD
$3.39 (2.71%)
- Volume
- 739.9K
- Average Volume
- 514.49K
- Market Capitalization
- $8.19B
- P/E Ratio
- 21.71
- Dividend Yield
- 1.47%
- Price Target
- $156.00
- Year High
- $164.28
- Year Low
- $103.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.31
- Current Ratio
- $1.66
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Stephan Tanda |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | ATR |
| CUSIP | 038336103 |
| CIK | 0000896622 |
| Web | https://www.aptar.com |
| Phone | 815 477 0424 |
| Currency | USD |
| Employees | 14000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.54 |
| Payout Ratio | 0.31 |
| Current Ratio | 1.66 |
| Quick Ratio | 1.14 |
| Cash Ratio | 0.21 |
Sales & Book Value
| Annual Sales | $3.78B |
| Price / Sales | 2.11 |
| Cash Flow | 5.08 |
| Price / Cash Flow | 25.15 |
| Price / Book | 3.12 |
Price Target and Rating
| Average Stock Price Forecast | $156.00 |
| High Stock Price Forecast | $156.00 |
| Low Stock Price Forecast | $156.00 |
| Forecast Upside/Downside | -17.77% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $5.88 |
| Trailing P/E Ratio | 21.71 |
| PEG Ratio | 3.67 |
| P/E Growth | 3.67 |
| Net Income | $392.79M |
| Net Margin | 9.98% |
| Pretax Margin | 12.37% |
| Return on Equity | 14.33% |
| Return on Assets | 7.58% |
Financials Score
| AltmanZ Score | 3.98 |
| Piotroski Score | 6.00 |
| Working Capital | 705.24M |
| Total Assets | 5.1B |
| Ebit | 537.46M |
| Market Cap | 7.97B |
| Total Liabilities | 2.42B |
Poll Results
About AptarGroup, Inc. (NYSE:ATR) Stock
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science in ... novations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
2026-07-14 06:30:00
-- ATR 1072 is the company's first precision cardiology program to enter the clinic -- -- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease -- SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. "PRKAG2 syndrome and other rare genetic cardiomyopathies represent a profound unmet need — these are progressive, life-altering and life-threatening diseases that often strike early, affect multiple members of the same family, and have no approved therapy to address their root cause," said Kathleen Gallagher, President and Chief Executive Officer, Atrium Therapeutics.
Aptar Releases 2025 Corporate Sustainability Report
2026-06-18 17:00:00
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Releases 2025 Corporate Sustainability Report.
2026-06-10 03:52:11
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
A Look at AptarGroup Inc (ATR) After 3.5% Gain -- GF Value $156.52 vs Price $115.90
2026-06-09 19:56:00
On June 09, 2026, AptarGroup Inc (ATR) shares rose 3.5% today, currently priced at $115.90. The stock has experienced a 52-week range of $103.23 to $164.28, ref
AptarGroup, Inc. (ATR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-03 15:52:02
AptarGroup, Inc. (ATR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year
2026-06-02 17:00:00
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year.
Aptar to Participate in Upcoming Investor Conferences
2026-05-27 17:00:00
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences.
AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
2026-05-09 18:07:16
AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
Frequently Asked Questions
-
What is the current AptarGroup, Inc. (ATR) stock price?
-
AptarGroup, Inc.(NYSE:ATR) stock price is $128.28 in the last trading session. During the trading session, ATR stock reached the peak price of $164.28 while $103.23 was the lowest point it dropped to. The percentage change in ATR stock occurred in the recent session was 2.71% while the dollar amount for the price change in ATR stock was $3.39.
-
ATR's industry and sector of operation?
-
The NYSE listed ATR is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of ATR?
-
Gael Touya | President of Aptar Pharma
Hedi Tlili | President of Aptar Closures
Marc Prieur | President of Aptar Beauty
Stephan Tanda | President, Chief Executive Officer & Executive Director
Vanessa Kanu | Executive Vice President & Chief Financial Officer -
How many employees does ATR have?
-
Number of ATR employees currently stands at 14000. ATR operates from 265 Exchange Drive, Crystal Lake, IL 60014, US.
-
Link for ATR official website?
-
Official Website of ATR is: https://www.aptar.com
-
How do I contact ATR?
-
ATR could be contacted at phone #815 477 0424 and can also be accessed through its website. ATR operates from 265 Exchange Drive, Crystal Lake, IL 60014, US.
-
How many shares of ATR are traded daily?
-
The average number of ATR shares traded daily for last 3 months was 514.49K.
-
What is the market cap of ATR currently?
-
The market value of ATR currently stands at $8.19B with its latest stock price at $128.28